Develops cell therapies and small-molecule drug candidates for patients with cancer and certain immune conditions.
10-K for FY2025, filed Mar 30, 2026We are a clinical-stage biotechnology company advancing a diversified portfolio of cell therapy and small molecule product candidates. In…View ↗
Our portfolio also includes two clinical-stage small molecule product candidates with the potential to treat certain cancer indications.…View ↗
Our cell therapy programs expand our oncology pipeline with a portfolio of next-generation CAR-T product candidates designed to potentially…View ↗
10-Q for Q3 FY2026, filed Nov 13, 2026
−$3.6MView ↗
8-K, filed Nov 12, 2026
On November 11, 2026, the Company exercised its option under its Exclusive Collaboration, Option and License Agreement, dated September 14…View ↗
8-K, filed Nov 6, 2026
The notification received has no immediate effect on the listing of the Company’s common stock on the Nasdaq Stock Market or on the…View ↗
8-K, filed Oct 30, 2026
On October 26, 2026, Ms. Constance Ames confirmed to Tempest Therapeutics, Inc. (the “Company”) that she would be resigning from her…View ↗
Cell therapy added
The older report centered on orally available small-molecule oncology therapies and preclinical drug programs. The latest report also includes autologous, allogeneic and in vivo CAR-T candidates for blood cancers, solid tumors and immunology indications.
10-K for FY2022, filed Mar 22, 2023 10-K for FY2025, filed Mar 30, 2026We are a clinical-stage oncology company focused on leveraging our deep scientific understanding of cancer biology and medicinal chemistry…View ↗
Competes with Ono, Adlai Nortye, Merck, Roche, Exelixis, AstraZeneca, Johnson & Johnson, Bristol Meyers Squibb, Gilead Sciences, Arcellx, Legend Biotech, Allogene, and Cellectis
10-K for FY2025, filed Mar 30, 2026If our current or any future product candidates are approved for the treatment of cancer, they may compete with existing therapies as well…View ↗
Loading...